Abstract
Researchers previously reported a benefit from 80 mg of atorvastatin daily in preventing recurrent cerebrovascular and cardiovascular events over 5 years after a first stroke or transient ischemic attack (TIA) in the randomized, placebo-controlled, manufacturer-sponsored SPARCL trial ( N Engl J Med 2006; 355:549; JW Cardiol Aug 30 2006). Now, the authors report subanalysis results. The 4731 participants had documented elevated LDL levels and stroke or TIA within the prior 6 …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
